Ons laatste Nieuws

According to sources familiar with the discussions, sanofi-aventis reached an agreement in principle to acquire Genzyme in a deal that includes a contingent value right (CVR). One of the sources noted that a deal could be finalised within the next week or two. Earlier on Monday it was disclosed in a SEC filing that the two companies signed a non-disclosure agreement, allowing the French drugmaker to conduct due diligence.

Commenting on the non-disclosure agreement, ISI Group analyst Mark Schoenebaum suggested that the companies were now likely to reach a deal valued at $74 per share, plus another $5 to $10 per share in potential payments linked to the performance of Genzyme's experimental multiple sclerosis drug Lemtrada (alemtuzumab).

Last week, sanofi-aventis extended its hostile $69-per share tender offer to acquire all outstanding shares of Genzyme to February 15, after the offer expired on January 21.